Erythroblastosis is a proliferative disease of the bone marrow with major clinical manifestations of hemorrhage, thrombosis and hepatosplenomegaly, which can be life-threatening in severe cases. What is the survival period of erythroblastosis? Experts say that erythroblastosis is a chronic disease that usually leads to death, and that the survival period is usually 10-20 years after diagnosis. Studies have shown that the median survival is about 13.9 years for patients treated with phlebotomy alone, 11.8 years for patients treated with 32P, and 8.9 years for patients treated with tumorconin. Approximately 31% of patients die from embolism, 19% from leukemia, 15% from other tumors, and 5% from bleeding or the end stage of true erythrocytosis.